Metagenomi Therapeutics Net Income 2022-2026 | MGX
Metagenomi Therapeutics net income from 2022 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Metagenomi Therapeutics Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-88 |
| 2024 | $-78 |
| 2023 | $-68 |
| 2022 | $-44 |
| 2021 | $-21 |
|
Metagenomi Therapeutics Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-23 |
| 2025-12-31 | $-23 |
| 2025-09-30 | $-20 |
| 2025-06-30 | $-20 |
| 2025-03-31 | $-25 |
| 2024-12-31 | $-23 |
| 2024-09-30 | $-19 |
| 2024-06-30 | $-11 |
| 2024-03-31 | $-25 |
| 2023-12-31 | $-19 |
| 2023-09-30 | $-20 |
| 2023-06-30 | $-13 |
| 2023-03-31 | $-16 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |